TP53 and prostate cancer: Chetah and colleagues found that co-culturing of LNCaP prostate cancer cells with primary human CAFs or CAF CM reduced p53 in prostate cancer cells, which inhibited drug-induced ROS in response to doxorubicin, taxol or mitomycin C to promote cell survival [278].